A systematic atlas of chaperome deregulation topologies across the human cancer landscape
Fig 5
Opposing chaperome deregulation in cancers and neurodegenerative diseases.
A—B. Heatmaps indicate significance of up or down-regulation of gene expression (∆GSA) of chaperome vs. non-chaperome genes (A) and chaperome functional families (B) in Alzheimer’s (AD), Huntington’s (HD), and Parkinson’s disease (PD) compared to age-matched healthy controls. Datasets: GSE5281 (AD, superior frontal gyrus) [42], GSE3790 (HD, nucleus caudatus) [43], and GSE20295 (PD, substantia nigra) [44]. ∆GSA values are in the interval [-1, +1], where ‘+1’ indicates significant upregulation (p value = 0), while ‘-1’ indicates significant downregulation (p value = 0) as in Fig 2. Functional families (columns) are ordered by increasing ∆GSA group mean change (bar graphs). Turquoise box highlights the human chaperome. C—D. Side-by-side comparison of gene expression changes (∆GSA) of chaperome vs. non-chaperome (C), and chaperome functional families (D) in cancers versus neurodegenerative diseases (NeuroD). Bar graphs show ∆GSA group mean changes in cancers (black) compared to NeuroD (grey).